Novocure is a leading oncology company believing in giving more reasons to release the stress of aggressive cancers via (Tumor Treating) TTFields therapy. The company utilize electric fields and markets Optune Lua and Optune for pleural mesothelioma and glioblastoma. Novocure tech-intensified knowledge and effective products are the main strength of the business and partnerships.
Novocure’s Optune Pax® finally received approval from the U.S. Food and Drug Administration (FDA) for the generally advanced pancreatic cancer adult patients, having nab-paclitaxel and gemcitabine. This new device is another core development in the healthcare sector.
Optune Pax is a commendable portable therapeutic device that serves TTFields without any painful surgical process, as this new device uses wearable arrays. The TTFields are like another option to the electric fields that focus on the electrical properties of cancer cells and support them in complicated activities/scenarios. Following the survival and cell division, this brings the cell to an end without any harm to healthy cells.
Optune Pax got the boost and approval due to the PANOVA-3 prospective, well-balanced Phase 3 clinical trial. The trial was conducted to assess the usage and incorporation of Optune Pax concomitantly with the nab-paclitaxel and gemcitabine. It was evaluated for the primary treatment of generally advanced pancreatic cancer in terms of gem/nab-pac alone.
In this trial total of 571 patient participants were involved for 18 months on 1:1 ratio. The trail was satisfying, the calculations were presentable and proven as per the study’s momentum. Optune Pax was found to be tolerable without worsening gem/nab-pac-based toxicity and negative impact. The patients treated with Optune Pax showed a moderate impact.
The CEO of Novocure, Frank Leonard, said, “Optune Pax approval represents a first-ever new treatment in this long age for patients suffering from the generally advanced pancreatic cancer. The systemic therapies have shown very dull bio-presence in the pancreatic tumors that has lessened the effectiveness.
“Optune Pax is an essential, unique treatment that uses a biophysical approach aiming at the different electrical properties of cancer cells. This is a memorable moment for the company, and we are excited to introduce Optune Pax to the healthcare providers and their patients.”
Anna Berkenblit, MD, MMSc and PanCAN’s Chief Scientific and Medical Officer, also showed excitement for this approval, stating that this is a huge success for the pancreatic cancer population.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
